Skip to main content
Bristol Myers SquibbPatent grant

Bristol-Myers Squibb was granted a patent for WEE1-degrading cancer compounds

Source: Autobound Signal API · 118 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

In November 2026 Bristol-Myers Squibb patented drug compounds designed for treating WEE1-related diseases, including cancer, in pharmaceutical and clinical settings.

Source

patents.google.comNov 17, 2026

US patent US12799098

WEE1 degrading compounds and uses thereof

Abstract

Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment of WEE1 associated diseases such as cancer. In some embodiments, the compound is a compound according to Formula (I) or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof.

patents.google.com/patent/US12799098Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
4
Patent number
US12799098
Assignee
Bristol-Myers Squibb Company

The full record

From the Signal API record

People

  • John SapienzaInventor
  • Jennifer R. RiggsInventor
  • Jacob T. EdwardsInventor
  • Daniel K. CashionInventor
  • Meekyum Olivia PierceInventor

Details

Primary CPC class
C07D 401/14
USPTO assignee
Bristol-Myers Squibb Company
What the invention does
Small-molecule compounds that lower levels of the WEE1 protein, which may help stop cancer cells from continuing to grow.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • small-molecule therapeutics
  • protein degradation
  • oncology

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/25fe9725-b645-56e5-9a1a-f6215c38f892 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "25fe9725-b645-56e5-9a1a-f6215c38f892",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:06:42+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 401/14"
      },
      {
        "code": "A61P 35/00"
      },
      {
        "code": "C07D 405/14"
      },
      {
        "code": "C07D 413/14"
      },
      {
        "code": "C07D 471/04"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 Bristol-Myers Squibb patented drug compounds designed for treating WEE1-related diseases, including cancer, in pharmaceutical and clinical settings.",
    "summary": "Bristol-Myers Squibb was granted a patent for WEE1-degrading cancer compounds",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "John Sapienza",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/john-sapienza-1ba63815"
      },
      {
        "name": "Jennifer R. Riggs",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Jacob T. Edwards",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Daniel K. Cashion",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Meekyum Olivia Pierce",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799098",
    "cpc_primary": {
      "code": "C07D 401/14"
    },
    "patent_title": "WEE1 degrading compounds and uses thereof",
    "patent_number": "US12799098",
    "uspto_assignee": "Bristol-Myers Squibb Company",
    "patent_abstract": "Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment of WEE1 associated diseases such as cancer. In some embodiments, the compound is a compound according to Formula (I) or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof.",
    "precision_class": "structural",
    "invention_explanation": "Small-molecule compounds that lower levels of the WEE1 protein, which may help stop cancer cells from continuing to grow.",
    "technologies_mentioned": [
      "small-molecule therapeutics",
      "protein degradation",
      "oncology"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.